Jun 15, 2026 03:00AM
Jun 12, 2026 06:44PM
Jun 12, 2026 02:03PM
Jun 2, 2026 08:02AM
Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM
May 28, 2026 09:18PM IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 28, 2026 12:42PM
May 27, 2026 04:04AM
May 22, 2026 10:17AM
May 22, 2026 10:16AM
May 22, 2026 09:30AM
May 22, 2026 09:30AM
May 22, 2026 08:00AM Enhertu gets EU panel backing for HER2 positive metastatic solid tumors
May 22, 2026 08:00AM
May 22, 2026 07:00AM
May 22, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 05:07AM
May 15, 2026 09:52PM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
May 15, 2026 06:31PM
May 14, 2026 07:00AM
May 1, 2026 05:44AM
Apr 30, 2026 09:42PM
Apr 30, 2026 11:49AM
Apr 28, 2026 01:46PM
Apr 28, 2026 07:03AM AstraZeneca's BREZTRI wins US approval for asthma treatment
Apr 28, 2026 07:00AM
Apr 27, 2026 07:03AM
Apr 27, 2026 07:00AM
Apr 20, 2026 07:01AM
Apr 7, 2026 02:09PM
Apr 2, 2026 07:00AM
Apr 2, 2026 07:00AM IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
Mar 24, 2026 10:30AM
Mar 9, 2026 08:45AM
Mar 9, 2026 07:00AM
Mar 9, 2026 02:30AM
Feb 20, 2026 07:01AM
Feb 20, 2026 07:00AM
Feb 19, 2026 05:28AM EMA validates ENHERTU application for early breast cancer treatment
Feb 19, 2026 02:30AM
Feb 3, 2026 07:00AM
Feb 3, 2026 07:00AM
Feb 3, 2026 04:11AM
Feb 3, 2026 02:30AM
Jan 19, 2026 02:30AM
Jan 13, 2026 07:00AM Daiichi Sankyo initiates phase 3 lung cancer trial with biomarker selection
Jan 13, 2026 07:00AM

323,442 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All